Adam K Wheatley
Overview
Explore the profile of Adam K Wheatley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
7702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burmas L, Lee W, Kelly A, Webster R, Esterbauer R, Kent S, et al.
J Immunol
. 2025 Mar;
PMID: 40073085
Human clinical trials have reported immunological outcomes can differ between ipsilateral (same side) and contralateral (alternate sides) prime-boost vaccination. However, our mechanistic understanding of how keeping or shifting the anatomical...
2.
Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P, et al.
Sci Adv
. 2025 Feb;
11(9):eads1482.
PMID: 40009690
Repeated mRNA COVID-19 vaccination increases spike-specific immunoglobulin G4 (IgG4) titers. Here, we characterized the influence of increased IgG4 titers on a range of Fc-mediated responses. Elevated spike-specific IgG4 reduced binding...
3.
Joyce M, Bu W, Chen W, Gillespie R, Andrews S, Wheatley A, et al.
Immunity
. 2025 Feb;
58(2):295-308.e5.
PMID: 39909035
Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with malignancies in humans. Viral infection of B cells is initiated by the viral glycoprotein 350 (gp350) binding to complement receptor...
4.
Lee W, Selva K, Audsley J, Kent H, Reynaldi A, Schlub T, et al.
JCI Insight
. 2025 Jan;
10(4).
PMID: 39786918
BACKGROUNDThe immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are...
5.
Pilapitiya D, Lee W, Vu M, Kelly A, Webster R, Koutsakos M, et al.
Vaccine
. 2024 Dec;
46():126668.
PMID: 39740385
Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal...
6.
Lederhofer J, Borst A, Nguyen L, Gillespie R, Williams C, Walker E, et al.
bioRxiv
. 2024 Dec;
PMID: 39677750
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the...
7.
Do T, Wille M, Wheatley A, Koutsakos M
J Virol
. 2024 Oct;
98(10):e0118624.
PMID: 39360825
Neuraminidase (NA)-specific antibodies have been associated with protection against influenza and thus NA is considered a promising target for next-generation vaccines against influenza A (IAV) and B viruses (IBV). NA...
8.
Cromer D, Reynaldi A, Mitchell A, Schlub T, Juno J, Wheatley A, et al.
Nat Commun
. 2024 Sep;
15(1):8395.
PMID: 39333473
The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based largely on...
9.
Kent S, Li S, Amarasena T, Reynaldi A, Lee W, Leeming M, et al.
ACS Nano
. 2024 Sep;
18(39):27077-27089.
PMID: 39298422
Lipid nanoparticle mRNA vaccines are an exciting but emerging technology used in humans. There is limited understanding of the factors that influence their biodistribution and immunogenicity. Antibodies to poly(ethylene glycol)...
10.
Rowntree L, Audsley J, Allen L, McQuilten H, Hagen R, Chaurasia P, et al.
Proc Natl Acad Sci U S A
. 2024 Sep;
121(39):e2411428121.
PMID: 39284068
Long COVID occurs in a small but important minority of patients following COVID-19, reducing quality of life and contributing to healthcare burden. Although research into underlying mechanisms is evolving, immunity...